Therapy options for metastatic triple negative breast cancer-Reference-Cited by-同舟云学术

Therapy options for metastatic triple negative breast cancer

Published:2022-06-19 Issue:9 Volume: Page:201-206
ISSN:2658-5790
Container-title:Meditsinskiy sovet = Medical Council
language:
Short-container-title:Medicinskij sovet

Author:

Glazkova E. V.¹^ORCID,Frolova M. A.¹^ORCID,Israelyan E. R.²^ORCID

Affiliation:

1. Blokhin National Medical Research Center of Oncology

2. Pirogov National Medical Research University

Abstract

Metastatic triple-negative breast cancer remains the most unfavourable among all breast cancer subtypes from the prognostic point of view. Despite the active introduction into practice of combinations of cytostatics with immunotherapeutic agents, as well as PARP inhibitors, sequential lines of chemotherapy with the median overall survival which does not exceed 15 months remains the main method of treating patients in this group. This breast cancer subtype is characterized by a rapid development of drug resistance at the early stages of systemic treatment and a predominantly visceral progression, which determines a low life expectancy in patients. The combination of capecitabine and ixabepilone has proved to be effective in the treatment of tumours that are resistant to taxanes and anthracyclines. The use of this combination is characterized by an acceptable and controlled toxicity profile. This article presents a clinical case of therapy with a combination of ixabepilone and capecitabine of a patient with breast cancer progression during the previous therapy of taxanes, a platinum-based doublet chemotherapy and eribulin. This approach, together with symptomatic laparocentesis and pleurodesis, allowed for overall survival exceeding 45 months with the preservation of a satisfactory functional status of the patient.

Publisher

Remedium, Ltd.

Subject

General Medicine

Reference20 articles.

1. Dent R., Hanna W.M., Trudeau M., Rawlinson E., Sun P., Narod S.A. Pattern of metastatic spread in triple-negative breast cancer. Breast Cancer Res Treat. 2009;115(2):423-428. https://doi.org/10.1007/s10549-008-0086-2.

2. Lu Y.-S., Im S.-A., Colleoni M., Franke F., Bardia A., Cardoso F. et al. Updated Overall Survival of Ribociclib plus Endocrine Therapy versus Endocrine Therapy Alone in Pre- and Perimenopausal Patients with HR + /HER2 -Advanced Breast Cancer in MONALEESA-7: A Phase III Randomized Clinical Trial. Clin Cancer Res. 2022:28(5):851-859. https://doi.org/10.1158/1078-0432.CCR-21-3032.

3. Schmid P., Adams S., Rugo H.S., Schneeweiss A., Barrios C.H., Iwata H. et al. Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. N Engl J Med. 2018;379(22):2108-2121. https://doi.org/10.1056/NEJMoa1809615.

4. Miles D., Gligorov J., Andre F., Cameron D., Schneeweiss A., Barrios C. et al. Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. Ann Oncol. 2021;32(8):994-1004. https://doi.org/10.1016/j.annonc.2021.05.801.

5. Cortes J., Cescon D.W., Rugo H.S., Nowecki Z., Im S.-A., Yusof M.M. et al. Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triplenegative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet. 2020;396(10265):1817-1828. https://doi.org/10.1016/S0140-6736(20)32531-9.